MedTrace Logo

Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab

NCT01197144 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-10-22

No results posted yet for this study

Summary

The purpose of this study is to obtain increased knowledge concerning central pain and fatigue processing in rheumatoid arthritis, and how these conditions are influenced by treatment with Tumor Necrosis Factor (TNF) blockade with adalimumab.

Conditions

Interventions

DRUG

adalimumab

Subcutaneous, 40 mg every other week for 4 weeks

DRUG

Placebo

Subcutaneous, every other week for 4 weeks

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Swedish Foundation for Strategic Research

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Lars Klareskog, Professor · Karolinska Institutet

  • Jon Lampa, MD, PhD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2016-11-28
Completion
2016-11-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01197144 on ClinicalTrials.gov